Skip to content

Capital Advantage, Inc.: CGMS position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Capital Advantage, Inc. on CGMS, newest first. How the timeline and the estimate are built.

Capital Advantage, Inc. held 3,791,682 CGMS shares at 2026-06-30 per its 13F-HR filed 2026-07-13.

the latest 13F is the newest step

  1. period ended2026-06-30
    13F 3,791,682 shares
    Change vs previous 13F +1,292,902 shares

    12.64% of the 13F portfolio, value $103,626,677.

    13F-HR 0002085853-26-000699 filed by Capital Advantage, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2026-03-31
    13F 2,498,780 shares
    Change vs previous 13F +190,612 shares

    8.89% of the 13F portfolio, value $68,041,791.

    13F-HR 0002085853-26-000344 filed by Capital Advantage, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-12-31
    13F 2,308,168 shares
    Change vs previous 13F +138,954 shares

    8.6% of the 13F portfolio, value $63,751,608.

    13F-HR 0002085853-26-000016 filed by Capital Advantage, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2025-09-30
    13F 2,169,214 shares
    Change vs previous 13F +60,898 shares

    9.05% of the 13F portfolio, value $60,195,690.

    13F-HR 0002085853-25-000139 filed by Capital Advantage, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2025-06-30
    13F 2,108,316 shares
    Change vs previous 13F not available

    9.22% of the 13F portfolio, value $58,231,678.

    13F-HR 0001667731-25-000784 filed by Capital Advantage, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).